跳至主要内容
临床试验/NCT03085940
NCT03085940已完成不适用

Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis

Indonesia University1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2017年1月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
37
试验地点
1
主要终点
Endothelial dysfunction marker

研究概览

简要总结

Rheumatoid arthritis (RA) increase cardiovascular risk and endothelial dysfunction. Hydroxychloroquine (HCQ) is expected to improve endothelial dysfunction through some metabolic effects. The investigators intend to find the role of HCQ to improve endothelial dysfunction in RA patients. This study will also evaluate correlation HOMA-IR (homeostasis model assessment-estimated insulin resistance), FFA (free fatty acid) and ox-LDL (oxidized-LDL) level change, with endothelial dysfunction improvement.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rheumatoid Arthritis patients (2010 ACR/EULAR criteria)
  • Being or will be treated with methotrexate (monotherapy)
  • Agree to join the study

排除标准

  • Autoimmune diseases other than RA
  • Acute severe infection, acute coronary syndrome, heart failure, stroke
  • Malignancy or chronic inflammatory diseases
  • Eye disease involving the retina and visual field defects
  • G6PD (glucose 6-phosphate dehydrogenase) deficiency
  • History of smoking within last 5 years
  • Lipid lowering, insulin resistance lowering, antidiabetic, insulin, ACE(angiotensin converting enzyme)-inhibitor or ARB(angiotensin receptor blocker) drugs

研究组 & 干预措施

Hydroxychloroquine

Experimental

干预措施: Hydroxychloroquine (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Endothelial dysfunction marker

时间窗: 3 months

E-Selektine

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rudy Hidayat

MD

Indonesia University

研究点 (1)

Loading locations...

相似试验

Role of Hydroxychloroquine to Improve Endothelial... | 临床试验